Breaking News

Europe Car Sales Set Record Growth Streak On VW, Ford Compacts
Tweet TWEET

Ark Therapeutics Grp AKT Re Agreement

  Ark Therapeutics Grp (AKT) - Re Agreement

RNS Number : 6485O
Ark Therapeutics Group PLC
15 October 2012




                                                                             

                                                                             

    Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for
       Production of Lymfactin^TM Investigational Treatment for Breast
                         Cancer-Associated Lymphedema



15 October 2012, London, UK Ark Therapeutics has been selected to  manufacture 
and supply  Lymfactin^TM to  Laurantis Pharma  under a  conditional  agreement 
announced today by the Finland-based  companies. The agreement is subject  to 
Laurantis receiving  regulatory  approval to  commence  its phase  I  clinical 
trial. Specific terms of the  agreement are not disclosed.Lymfactin^TM  uses 
an adenoviral vector  to deliver vascular  endothelial growth factor  (VEGF-C) 
during transplantation of lymph nodes in order to avoid lymphedema.



The  phase   I   clinical   trial   using   Lymfactin^TM   to   treat   breast 
cancer-associated lymphedema is targeted  to begin in  2013, and will  recruit 
patients in the USA and  Finland. Breast cancer-associated lymphedema is  the 
most common form of  secondary lymphedema, occurring  in approximately 20%  of 
breast cancer  patients  who  undergo  axillary  lymph  node  dissection.  The 
incidence is even  higher in  those who  also receive  radiotherapy, and  this 
complication may even occur in those who  undergo a lymph node biopsy as  part 
of treatment. No therapeutic treatment currently exists to treat this disease.



In  the   US,  approximately   110,000  patients   are  living   with   breast 
cancer-associated lymphedema,  and  nearly  15,000 new  patients  develop  the 
complication each  year.  The  number  of lymphedema  patients  in  Europe  is 
estimated to be roughly the same as in the US.



For further information:



  Ark Therapeutics Group plc   Tel: +44 (0)20 7388 7722
  Dr David Venables, CEO       
  Iain Ross, Chairman          
                              
  Laurantis Pharma Oy          Tel: +1 202 422-6999
  David Sheon                  
                              
  FTI Consulting               Tel: +44 (0)20 7831 3113
  Ben Atwell                   
  Susan Stuart                 
                              





About Laurantis Pharma Oy

Based  in  Turku,  Finland,  Laurantis  is  a  privately  held  clinical-stage 
biotechnology company with a broad portfolio of first-in-class products  based 
on two proprietary technologies.  The Company's pipeline includes  proprietary 
and patent-protected  formulations and  applications of  cis-urocanic acid,  a 
locally  acting  anti-inflammatory  and   anti-proliferative  agent  for   the 
treatment of Atopic  Dermatitis, Dry Eye,  Interstitial Cystitis, and  Bladder 
Cancer. Laurantis is also developing Lymfactin™, a vascular endothelial growth
factor C (VEGF-C) in an adenoviral vector,  as a gene therapy product for  the 
treatment of secondary lymphedema.



About Ark Therapeutics Group plc

Ark Therapeutics  Group  plc  is  a leading  viral  product  focused  contract 
development  and  manufacturing  services   company  with  world-class   viral 
research, development and GMP manufacturing operations in Finland and the  UK. 
Ark's business model  is to  offer product development  and GMP  manufacturing 
contract services for viral  products, including the  areas of viral  mediated 
gene therapy, oncolytic  viral vaccines, live  and attenuated viral  vaccines, 
viral vectored vaccines and virus like particles. Ark's capabilities span from
translational research through preclinical  and clinical product  development, 
in addition to process and analytical development, GMP manufacture and sterile
filling  from  pre-clinical  through  to  commercial  product  supply.   These 
capabilities have  been  established  through the  development  of  Ark's  own 
products through to  Marketing Authorisation Application  registered with  the 
European Medicines Agency. Following  a change in  business strategy in  2011, 
Ark  is  now   building  its   business  through   contract  development   and 
manufacturing services  and  is seeking  external  partners to  advance  those 
products it previously had under development.



Ark's shares were  first listed  on the London  Stock Exchange  in March  2004 
(AKT.L).





This announcement  includes  "forward-looking statements"  which  include  all 
statements other  than  statements  of historical  facts,  including,  without 
limitation, those regarding the Group's financial position, business strategy,
plans  and  objectives   of  management  for   future  operations   (including 
development  plans  and  objectives  relating  to  the  Group's  products  and 
services), and  any  statements  preceded  by, followed  by  or  that  include 
forward-looking  terminology  such   as  the   words  "targets",   "believes", 
"estimates",   "expects",   "aims",    "intends",   "will",   "can",    "may", 
"anticipates", "would",  "should",  "could"  or  similar  expressions  or  the 
negative thereof. Such  forward-looking statements involve  known and  unknown 
risks, uncertainties and  other important factors  beyond the Group's  control 
that could cause the actual results, performance or achievements of the  Group 
to be materially  different from future  results, performance or  achievements 
expressed or implied by such forward-looking statements. Such  forward-looking 
statements are based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group will operate
in the future. Among the important factors that could cause the Group's actual
results, performance  or  achievements  to differ  materially  from  those  in 
forward-looking  statements   include   those  relating   to   Ark's   funding 
requirements,  regulatory  approvals,  clinical  trials,  reliance  on   third 
parties,  intellectual  property,  key  personnel  and  other  factors.  These 
forward-looking statements speak only as at the date of this announcement. The
Group expressly disclaims  any obligation  or undertaking  to disseminate  any 
updates or  revisions  to any  forward-looking  statements contained  in  this 
announcement to reflect  any change  in the Group's  expectations with  regard 
thereto or any change in events, conditions or circumstances on which any such
statements are based. As a result of these factors, readers are cautioned  not 
to rely on any forward-looking statement.

                                      

                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


AGRBKNDNPBDDQKD -0- Oct/15/2012 06:00 GMT
 
Press spacebar to pause and continue. Press esc to stop.